Retatrutide: The Weight-Loss Drug Everyone’s Talking About (and What the Science Actually Says)

Retatrutide is one of the most talked-about drugs in medicine and one of the most misunderstood. It isn’t approved anywhere, yet it’s already being sold online. Here’s what the research shows.

What is Retatrutide?

Retatrutide (“reta”) is an experimental once-weekly injection from Eli Lilly. It’s a first-in-class triple agonist that targets the GIP, GLP-1 and glucagon receptors. The first two hormones reduce appetite and improve blood sugar control. The third, glucagon, may also increase energy expenditure. lilly

How it differs from Ozempic and Mounjaro

All three drugs are weekly injections that mimic gut hormones, but they differ in how many hormone receptors they target:

•  Ozempic/Wegovy (semaglutide) targets one receptor, GLP-1. Ozempic is the diabetes brand and Wegovy is the weight-loss brand of the same drug.

•  Mounjaro/Zepbound (tirzepatide) targets two receptors, GLP-1 and GIP.

•  Retatrutide adds a third, glucagon.

That extra hormone appears to matter. Across separate trials in people without diabetes, weight loss climbs with each step up:

For context, 57% of people on 15 mg tirzepatide lost at least 20% of their body weight, while 45.3% on retatrutide lost at least 30%. In people with type 2 diabetes the gap holds. Semaglutide produced 9.6% weight loss in the STEP-2 trial, tirzepatide 14.7% in SURMOUNT-2, and retatrutide up to 20.8% in TRIUMPH-2. This site is intended for healthcare professionals only +4

An important caution: these are different trials with different populations, lengths and designs, not a fair race. A head-to-head trial against tirzepatide, TRIUMPH-5, is in the pipeline and will give a cleaner answer. glp3

Other differences:

•  Side effects. The profile looks broadly similar (nausea, diarrhea, vomiting), with dose-related heart-rate increases and tingling or skin sensitivity (dysesthesia) as the points to watch. Dysesthesia also appears in current semaglutide and tirzepatide labels. glp3

•  Stopping. None of these drugs is a one-time fix. After semaglutide, people who kept taking it lost a further 7.9%, while those switched to placebo regained 6.9%. Tirzepatide shows a similar rebound. Retatrutide’s stop-and-regain data is still limited, so assume the same. powerpak

•  Availability. Semaglutide and tirzepatide are approved and prescribed worldwide. Retatrutide is not.

The benefits

Beyond the scale, the research points to wider metabolic benefits. A 2023 Phase 2 trial in NEJM reported around 24% weight loss at 48 weeks. In Phase 3’s TRIUMPH-3, the top dose cut triglycerides by 37.0%, systolic blood pressure by 9.3 mmHg and the inflammation marker hsCRP by 51.2%. Other trials looked at knee osteoarthritis pain and sleep apnea. Lilly says these results were presented at ADA 2026 and published in NEJM. lillylilly

The risks

•  Digestive effects. In Phase 2, nausea, diarrhea, vomiting and constipation were the most common events, and 6 to 16% of retatrutide participants stopped because of side effects, versus none on placebo. In TRIUMPH-1, nausea affected 42.4% on 12 mg versus 14.8% on placebo. nejmglp3

•  Dysesthesia. Altered skin sensation affected 12.5% in TRIUMPH-1 at 12 mg versus 0.9% on placebo, mostly resolving during treatment. glp3

•  Heart rate. In Phase 2, heart rate rose dose-dependently, peaked around 24 weeks, then declined. nejm

•  Dropouts. In TRIUMPH-3, 13.5% on 12 mg stopped due to side effects versus 4.8% on placebo. lilly

Long-term safety data is limited, and most Phase 3 results so far come from company announcements and conference presentations rather than independent analysis.

Who might benefit?

Retatrutide isn’t approved, so no one can say yet who it will be prescribed for. The trials suggest the likely candidates, based on who was studied:

•  Adults with obesity (or overweight plus a health condition). This was the population in TRIUMPH-1.

•  People with type 2 diabetes and obesity. TRIUMPH-2 showed substantial weight loss and improved glycemic control. lilly

•  People with severe obesity and heart disease. This was the focus of TRIUMPH-3, where cardiovascular risk markers improved.

•  People with obesity-related knee osteoarthritis or sleep apnea. Both were studied in the Phase 3 program. TRIUMPH-4 reported 28.7% weight loss at 12 mg over 68 weeks in people with obesity and knee osteoarthritis. retatrutide

•  People who haven’t reached their goals on existing drugs. This seems plausible given the larger average weight loss, but it hasn’t been formally tested.

It’s unlikely to be suited to people at a healthy weight or those who need only modest weight loss. For some, the existing drugs may be enough, and they come with years of safety data. Whether someone is a good candidate will ultimately be a decision for them and their doctor.

The big caveat: it isn’t approved

Lilly plans to submit its FDA application in the first quarter of 2027, so retatrutide isn’t available by prescription anywhere. That hasn’t stopped a grey market selling vials labeled “for research use only.” Public Citizen documented at least 14 hospitalizations linked to its use. It also found that the FDA has sent 14 warning letters since 2024, yet 11 of those sellers were still advertising unapproved peptides as of May 2026. The risks include the drug’s unknowns outside a monitored trial, plus impurities, mislabeling and dosing errors in unregulated products. Trade press also notes that the FDA says retatrutide cannot be used in compounding under federal law. Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C +4

The bottom line

Retatrutide looks like the most powerful weight-loss drug tested so far, with weight loss approaching that of bariatric surgery and improvements in heart-health markers. Its side effects resemble those of Ozempic and Mounjaro, with a few new questions. But “promising in trials” isn’t “proven and safe,” especially from an unregulated vial. For now, the sensible routes are approved drugs through a doctor or a legitimate clinical trial.

This article is general information, not medical advice. Please talk to a qualified healthcare professional about any weight-loss treatment.

---

Sources

•  Jastreboff et al., Retatrutide for Obesity: A Phase 2 Trial, NEJM (2023)

•  Eli Lilly, TRIUMPH-1 results (May 2026)

•  Eli Lilly, TRIUMPH-2 and TRIUMPH-3 results (July 2026)

•  Eli Lilly, What to know about retatrutide

•  Wilding et al., Semaglutide 2.4 mg (STEP 1), NEJM (2021)

•  Jastreboff et al., Tirzepatide for Obesity (SURMOUNT-1), NEJM (2022)

•  Healio, SURMOUNT-1 coverage and SURMOUNT-2 coverage

•  PowerPak, Semaglutide for weight loss: STEP trials

•  Public Citizen, The “Miracle Drug” and the Peptide Craze Breaking the FDA

•  Drug Topics, Some Providers Prescribe Unapproved Retatrutide (June 2026)

•  Secondary summaries: glp3.wiki side-effects, glp3.wiki trial tracker and Peptide Journal on SURMOUNT